Literature DB >> 17245075

Pathophysiology of diabetic macular edema.

Antonia M Joussen1, Neil Smyth, Carien Niessen.   

Abstract

Diabetic maculopathy is the leading cause of visual loss in diabetic patients. The pathogenesis is not fully understood and a satisfactory therapy is currently not available. Malfunction of the blood-retinal barrier plays a central role in the disease and leads to retinal edema and secondary photoreceptor dysfunction. Diabetic vascular leakage and macular edema are regulated by a distinct combination of direct paracellular transport, alterations in endothelial intercellular junctions and endothelial cell death. The distribution and relevance of these three factors to diabetic maculopathy varies over the course of the disease. Cumulative endothelial cell death will become more relevant after prolonged diabetic conditions. This article reviews the current knowledge on the pathogenic mechanisms of diabetic macular edema.

Entities:  

Mesh:

Year:  2007        PMID: 17245075     DOI: 10.1159/000098495

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  33 in total

1.  Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.

Authors:  G Ratnarajan; F Mellington; M Saldanha; S R de Silva; L Benjamin
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

2.  Kallikrein-kinin activation by altered vitreous pH: New perspectives for treatment and pathogenesis of diabetic macular edema? : Comment on: Gao BB et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007 Feb;13(2):181-8.

Authors:  O Zeitz; M Keserü
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-06       Impact factor: 3.117

3.  Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy.

Authors:  Haitao Liu; Emma M Lessieur; Aicha Saadane; Sarah I Lindstrom; Patricia R Taylor; Timothy S Kern
Journal:  Diabetologia       Date:  2019-10-14       Impact factor: 10.122

4.  Association between cystoid spaces on indocyanine green hyperfluorescence and optical coherence tomography after vitrectomy for diabetic macular oedema.

Authors:  S Yoshitake; T Murakami; A Uji; K Ogino; T Horii; M Hata; S Arichika; K Nishijima; N Yoshimura
Journal:  Eye (Lond)       Date:  2014-01-24       Impact factor: 3.775

5.  Volcano like pattern in optical coherence tomography in chronic diabetic macular edema.

Authors:  Sivakami A Pai; Nazimul Hussain; Sudhira P Hebri; Afra M Lootah; Moza A Dekhain
Journal:  Saudi J Ophthalmol       Date:  2014-03-24

6.  Laser speckle analysis of retinal vascular dynamics.

Authors:  Anastasiia Y Neganova; Dmitry D Postnov; Jens Christian B Jacobsen; Olga Sosnovtseva
Journal:  Biomed Opt Express       Date:  2016-03-18       Impact factor: 3.732

Review 7.  Clinical Applications of Dexamethasone for Aged Eyes.

Authors:  Beatriz Abadia; Pilar Calvo; Antonio Ferreras; Fran Bartol; Guayente Verdes; Luis Pablo
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

8.  Prospective microperimetry and OCT evaluation of efficacy of repeated intravitreal bevacizumab injections for persistent clinically significant diabetic macular edema.

Authors:  Romualdo Malagola; Giovanni Spinucci; Carmela Cofone; Luigi Pattavina
Journal:  Int Ophthalmol       Date:  2012-12-14       Impact factor: 2.031

Review 9.  Advances in the medical treatment of diabetic retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

Review 10.  The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.

Authors:  Rafael Simó; Marta Villarroel; Lídia Corraliza; Cristina Hernández; Marta Garcia-Ramírez
Journal:  J Biomed Biotechnol       Date:  2010-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.